Pneumococcal immunisation in the 21st century

Journal of Infection

Volumn 56, Issue 1, 2008, Pages 13-19

  Williams, Craig ^a   Masterton, Robert ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Herd immunity; Pneumococcal vaccination

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ERYTHROMYCIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION RISK; MASS IMMUNIZATION; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; VACCINE FAILURE;

AGED; AGED, 80 AND OVER; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; IMMUNIZATION; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 37149049860     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.08.009     Document Type: Review

References (39)

1. Fedson D.S. Pneumococcal vaccine. In: Plotkin S.A., and Mortimer E.A. (Eds). Vaccines (1988), WB Saunders, Philadelphia, PA 271-299
2. Joint Committee on Vaccination and Immunisation Website: http://www.advisorybodies.doh.gov.uk/jcvi/.
3. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infection, including the use of the pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106 (2000) 362-366
4. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C.C., and Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumonia. J Clin Microbiol 45 4 (2007) 1225-1233
5. Tuomanen El., Austrian R., and Masure H.R. Pathogenesis of pneumococcal infection. N Engl J Med 332 19 (1995) 1280-1284
6. Ispahani P., Slack R.C.B., Donald F.E., Weston V.C., and Rutter N. Twenty years surveillance of invasive pneumococcal disease in Nottingham call in serogroups responsible and implications for immunisation. Arch Dis Childhood 89 (2004) 757-762
7. McIntosh E.D. How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine?. Arch Dis Child 88 (2003) 859-861
8. Applebaum P.C. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 34 (2002) 1613-1620
9. Douglas R.M., Paton J.C., Duncan S.J., and Hansman D.J. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 148 (1983) 131-137
10. Eastham K.M., Freeman R., Kearns A.M., Eltringham G., Clark J., Leeming J., et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax 59 6 (2004) 522-525
11. Byington C.L. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 25 3 (2006) 250-254
12. Calbo E., Diaz A., Canadell E., Fabrega J., Uriz S., Xercavins M., et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 12 9 (2006) 867-872
13. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 (2000) 187-195
14. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 (2001) 403-409
15. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 (2006) 740-748
16. Veenhoven R., Bogaert D., Uiterwaal C., Brouwer C., Kiezebrink H., Bruin J., et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361 (2003) 2189-2195
17. van Heerbeek N., Straetemans M., Wiertsema S.P., Ingels K.J., Rijkers G.T., Schilder A.G., et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 117 3 (2006) 603-608
18. Borgono J.M., McLean A.A., Vella P.P., Woodhour A.F., Canepa I., Davidson W.L., et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 157 (1978) 148-154
19. Blum M.D., Dagan R., Mendelman P.M., Pinsk V., Giordani M., Li S., et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 18 (2000) 2359-2367
20. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362 (2003) 355-361
21. Nachman S. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 112 1 (2003) 66-73
22. Ramani R.R., Hall W.N., Boulton M.J., Johnson D.R., and Zhu B.P. Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study. Am J Public Health 94 6 (2004) 958-959
23. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein - polysaccharide conjugate vaccine. N Engl J Med 348 (2004) 1737-1746
24. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR 16 36 (2005) 893-897
25. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., and Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25 (2006) 494-501
26. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22 (2004) 4203-4214
27. McIntosh E.D., Conway P., Willingham J., Hollingsworth R., and Lloyd A. Pneumococcal pneumonia in the UK - how herd immunity affects the costeffectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 25 (2005) 1739-1745
28. McIntosh E.D., Conway P., Willingham J., and Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 21 (2003) 2564-2572
29. Kaplan S.L., Mason Jr. E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 (2004) 443-449
30. Felmingham D., White A.R., Jacobs M.R., Appelbaum P.C., Poupard J., Miller L.A., et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 56 (2005) ii3-ii21
31. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 (2006) 1455-1463
32. Cohen R., Levy C., de La Rocque F., Gelbert N., Wollner A., Fritzell B., et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 25 (2006) 1001-1007
33. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 (2007) 123-128
34. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193 (2006) 1487-1494
35. Doit C., Loukil C., Geslin P., and Bingen E. Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children. J Clin Microbiol 40 8 (2002) 2994-2998
36. Decousser J.W., Ovetchkine P., and Collignon A. Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ile de France area. Eur J Clin Microbiol Infect Dis 23 (2004) 27-33
37. The Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. CDC MMWR 49 RR-9 (2000) 1-35
38. Serrano I., Ramirez M., and Melo-Cristino J. Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy. Clin Microbiol Infect 10 (2004) 652-656
39. Jacobs M.R., and Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Semin Pediatr Infect Dis 15 (2004) 5-20